 | LYSOPHOSPHOLIPIDS AND EICOSANOIDS IN BIOLOGY AND PATHOPHYSIOLOGY
Copyright © 2000 by the New York Academy of Sciences
description
Annals of the New York Academy of Sciences 905:34-53 (2000)
© 2000 New York Academy of Sciences
Pharmacological Characterization of Phospholipid Growth-Factor Receptors
GABOR TIGYIa,d,
DAVID J. FISCHERa,
DANIEL BAKERa,
DE-AN WANGa,
JUNMING YUEa,
NORA NUSSERa,
TAMAS VIRAGa,
VERONIKA ZSIROSa,
KAROLY LILIOMa,
DUANE MILLERb AND
ABBY PARRILLc
aDepartment of Physiology, The University of Tennessee, Memphis, 894 Union Avenue, Memphis, Tennessee 38163, USA
bDepartment of Pharmaceutical Science, The University of Tennessee, Memphis, 894 Union Avenue, Memphis, Tennessee 38163, USA
cComputational Research on Materials Institute, Department of Chemistry, The University of Memphis, Memphis, Tennessee 38152, USA
dCorresponding author. Voice: 901/448-4793; fax: 901/448-7126.
gtigyi{at}physio1.utmem.edu
The phospholipid growth-factor (PLGF) terminology is proposed to describe a group of endogenous glycerol- and sphingolipid mediators that regulate cell proliferation through plasma membrane receptors. In addition to LPA and SPP, multiple PLGFs are present in blood plasma and serum. PLGF activity is regulated by its stimulus-coupled production and by endogenous inhibitors. In addition to LPA and SPP, alkenyl-glycerophosphate, cyclic-phosphatidic acid, and sphingosylphosphorylcholine were detected in biological fluids using mass spectrometry. Heterologous desensitization studies indicate the expression of multiple LPA-activated receptors in a variety of cell types, which are differentially activated by the different PLGFs. Northern blot and RT-PCR results reinforce the coexpression of PSP24  and different members of the EDG1-7 receptors in the same cell. Stable heterologous expression of the PSP24 , EDG2, and EDG4 receptors in HEK293 cells show distinct PLGF specificities and dose-response properties for each receptor subtype. Thus, both the controlled availability of the different agonists/inhibitors and the regulated expression of their receptors regulate the biological effects of PLGFs.
This article has been cited by other articles:
|
|
|
|
 
W. Deng, D.-A. Wang, E. Gosmanova, L. R. Johnson, and G. Tigyi
LPA protects intestinal epithelial cells from apoptosis by inhibiting the mitochondrial pathway
Am J Physiol Gastrointest Liver Physiol,
May 1, 2003;
284(5):
G821 - G829.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D.-A. Wang, H. Du, J. H. Jaggar, D. N. Brindley, G. J. Tigyi, and M. A. Watsky
Injury-elicited differential transcriptional regulation of phospholipid growth factor receptors in the cornea
Am J Physiol Cell Physiol,
December 1, 2002;
283(6):
C1646 - C1654.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
W. B. Thoreson, J. S. Ryan, C. Shi, M. E. Kelly, E. J. Bryson, M. L. Toews, T. L. Ediger, and D. M. Chacko
Lysophosphatidic Acid Receptor Signaling in Mammalian Retinal Pigment Epithelial Cells
Invest. Ophthalmol. Vis. Sci.,
July 1, 2002;
43(7):
2450 - 2461.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
X. Fang, S. Yu, J. L. Tanyi, Y. Lu, J. R. Woodgett, and G. B. Mills
Convergence of Multiple Signaling Cascades at Glycogen Synthase Kinase 3: Edg Receptor-Mediated Phosphorylation and Inactivation by Lysophosphatidic Acid through a Protein Kinase C-Dependent Intracellular Pathway
Mol. Cell. Biol.,
April 1, 2002;
22(7):
2099 - 2110.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
D. J. Fischer, N. Nusser, T. Virag, K. Yokoyama, D.-a. Wang, D. L. Baker, D. Bautista, A. L. Parrill, and G. Tigyi
Short-Chain Phosphatidates Are Subtype-Selective Antagonists of Lysophosphatidic Acid Receptors
Mol. Pharmacol.,
October 1, 2001;
60(4):
776 - 784.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
K.'i. Hayashi, M. Takahashi, W. Nishida, K. Yoshida, Y. Ohkawa, A. Kitabatake, J. Aoki, H. Arai, and K. Sobue
Phenotypic Modulation of Vascular Smooth Muscle Cells Induced by Unsaturated Lysophosphatidic Acids
Circ. Res.,
August 3, 2001;
89(3):
251 - 258.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
